rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma
| Autor: | I. Philip, E. Bouffet, C. Coze, G. Andreu, M. C. Favrot, D. Floret, J. Michon, M. Gaspard, C. R. Franks, S. Negrier, T. Philip, P. Cochat |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Melphalan
Oncology medicine.medical_specialty Vincristine biology business.industry medicine.medical_treatment Immunotherapy Major histocompatibility complex medicine.disease Natural killer cell medicine.anatomical_structure Immune system Antigen Internal medicine Neuroblastoma medicine biology.protein business medicine.drug |
| Zdroj: | Cytokines in Hemopoiesis, Oncology, and AIDS ISBN: 9783540522812 |
| Popis: | Considerable progress has been achieved in the treatment of stage IV neuroblastoma in children over 1 year of age. Induction therapy and surgery followed by vincristine, high-dose melphalan, total body irridiation, and autologous bone marrow transplantation (ABMT) enable the achievement of 40% progression-free survival at 2 years post-transplantation [1]. However, late relapses occurring up to 72 months post-graft, with a projected disease- free survival at 5 years of only 20% to 25%, are a major concern. Therefore, new therapeutic approaches are needed; spontaneous regression of this tumor in children below 1 year of age favors a role of the immune system in antitumoral defense and the potential benefit of immunotherapy. However, since neuroblastoma cells lack class I and II major histocompatibility complex (MHC) antigens, any attempt to stimulate antitumoral defense should involve non-MHC-restricted immunity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|